Hereditary Breast and Ovarian Cancer: Which Patients Are at High Risk?
Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.
Metastatic Melanoma: Timely Approval of Yervoy
After a long fight with melanoma, the Roman Catholic parish priest Father Arthur Humphrey was able to receive the immunotherapeutic agent Yervoy, which greatly improved his prognosis.
Essential Components of Survivorship Care
At the 2012 NCCN annual meeting, a panel of oncology nurses discussed the essential components of healthcare for survivors, challenges survivors face, and survivorship program models.
Challenges With Managing Oral Cancer Treatments
Although oral treatments have revolutionized cancer care, their use presents challenges to both patients and providers.
Challenges and Breakthroughs in Cancer Pain Management
Cancer pain management has greatly improved with advances in oral and intravenous medication. However, several challenges still exist in administration.
Managing Dermatologic Toxicities Associated With Targeted Therapies
Many targeted therapies are associated with dermatologic side effects; the monitoring and treating of these side effects should be done on an individual patient basis.
Genetic Assessment of Breast and Ovarian Cancer Risk
Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.
National Comprehensive Cancer Network: Beyond the Treatment Guidelines
Each year at its annual meeting, the National Comprehensive Cancer Network presents updates to its Clinical Practice Guidelines in Oncology.
Lenvatinib Plus Pembrolizumab Elicits Durable Responses in Patients With Endometrial Cancer
Carolina Frailty Index Score May Be Applicable in Assessment of Patients with Ovarian Cancer
GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
2 Clarke Drive Cranbury, NJ 08512